February 4, 2019
Takeda Pharmaceutical is withdrawing its US application for an additional indication of its multiple myeloma (MM) drug Ninlaro (ixazomib) for use in post-transplant maintenance settings, planning a resubmission after it obtains overall survival (OS) data. Takeda CFO Costa Sarouko revealed...read more